Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Bullboard Posts
Post by Findingmoneyon Aug 12, 2020 5:04pm
181 Views
Post# 31400291

This is why SONA is different

This is why SONA is different

From the SONA site
Gold nanorods (GNRs) are small particles whose surface plasmon resonance (SPR) frequencies can be altered as a function of the length and width, giving these anisotropic particles optical properties useful in a host of applications (1,2). GNRs have been used in a number of biomedical applications, including as contrast agents for optical biomedical imaging and for their hyperthermal effects. One of the major barriers in the application of GNR-based materials, especially for in-vivo applications such as hyperthermal cancer treatment, is the efficient exchange and removal of cetyltrimethylammonium bromide (CTAB), the surfactant used exclusively in the large scale synthesis of GNRs. CTAB is a cytotoxiccationic surfactant with an extremely low critical micelle concentration (3-5). Its function in the synthesis of the gold nanorods is still a matter of debate, but it is generally thought that the CTAB forms a strongly adsorbed bilayer around the surface of the growing gold particle (6-8).

The concentration of CTAB that is most often used in the synthesis of gold nanorods is 0.10 M or 100 times its critical micelle concentration, meaning a significant amount of CTAB remains in the bulk of the solution after the GNRs are made, which serves to stabilize the GNRs (prevents them from selfaggregating in solution)(6). The CTAB surfactant, so critical for GNR synthesis, is a significant impediment to in-vivo applications. A number of methods have been used to “remove” or partially exchange the CTAB including frequent solvent washing, treatments with surface active materials such as PEGylated thiols or other polymers (9-11). However, during surface exchange CTAB-coated GNR dispersions are destabilized, which results in particle aggregation and low recovery yields of GNRs. In addition, these surface modified GNRs are often contaminated with residual CTAB (9).


Bullboard Posts